The Clorox Company (NYSE:CLX – Get Free Report) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,760,000 shares, an increase of 18.6% from the October 31st total of 3,170,000 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is currently 3.1 days.
Clorox Stock Down 0.4 %
Shares of NYSE CLX opened at $166.54 on Tuesday. The company has a 50 day simple moving average of $163.13 and a 200-day simple moving average of $149.68. The company has a market capitalization of $20.61 billion, a P/E ratio of 58.00, a P/E/G ratio of 3.09 and a beta of 0.42. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62. Clorox has a 1 year low of $127.60 and a 1 year high of $171.35.
Clorox (NYSE:CLX – Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. The firm had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The firm’s quarterly revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the company posted $0.49 EPS. On average, equities research analysts predict that Clorox will post 6.85 earnings per share for the current year.
Clorox Dividend Announcement
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on CLX. Citigroup increased their target price on shares of Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. BNP Paribas upgraded shares of Clorox to a “strong sell” rating in a research report on Friday, September 6th. Evercore ISI reduced their price target on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a research report on Monday, October 14th. Jefferies Financial Group upgraded shares of Clorox from a “hold” rating to a “buy” rating and upped their price target for the stock from $174.00 to $187.00 in a research report on Tuesday, October 1st. Finally, Barclays upped their price target on shares of Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a research report on Friday, November 1st. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $155.00.
Read Our Latest Research Report on CLX
Insider Buying and Selling at Clorox
In other news, EVP Angela C. Hilt sold 1,733 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total transaction of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares of the company’s stock, valued at $2,229,719.92. This represents a 11.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.57% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Clorox
A number of hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its position in Clorox by 7.2% in the 1st quarter. Janus Henderson Group PLC now owns 20,805 shares of the company’s stock valued at $3,185,000 after buying an additional 1,400 shares during the period. Comerica Bank boosted its position in Clorox by 10.5% in the 1st quarter. Comerica Bank now owns 39,390 shares of the company’s stock valued at $6,031,000 after buying an additional 3,740 shares during the period. Swedbank AB purchased a new position in Clorox in the 1st quarter valued at approximately $6,523,000. Atria Investments Inc boosted its position in Clorox by 3.8% in the 1st quarter. Atria Investments Inc now owns 17,923 shares of the company’s stock valued at $2,744,000 after buying an additional 653 shares during the period. Finally, Cetera Investment Advisers boosted its position in Clorox by 140.6% in the 1st quarter. Cetera Investment Advisers now owns 74,032 shares of the company’s stock valued at $11,335,000 after buying an additional 43,265 shares during the period. Hedge funds and other institutional investors own 78.53% of the company’s stock.
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Featured Stories
- Five stocks we like better than Clorox
- 3 Grocery Stocks That Are Proving They Are Still Essential
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 S&P 500 Stocks With Sky High Risk-Adjusted Returns
- How to Most Effectively Use the MarketBeat Earnings Screener
- Trending Stocks: How to Spot, Trade, and Profit Safely
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.